Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

IMPORTANCE: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. OBJECTIVE: To determine maximum tolerated doses (MTDs) of trastuzumab emtansine (T-DM1) plus capecitabine i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés, Javier, Diéras, Véronique, Lorenzen, Sylvie, Montemurro, Filippo, Riera-Knorrenschild, Jorge, Thuss-Patience, Peter, Allegrini, Giacomo, De Laurentiis, Michelino, Lohrisch, Caroline, Oravcová, Eva, Perez-Garcia, Jose M., Ricci, Francesco, Sakaeva, Dina, Serpanchy, Rosanne, Šufliarský, Jozef, Vidal, Maria, Irahara, Natsumi, Wohlfarth, Christine, Aout, Mounir, Gelmon, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317656/
https://www.ncbi.nlm.nih.gov/pubmed/32584367
http://dx.doi.org/10.1001/jamaoncol.2020.1796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317656/
https://www.ncbi.nlm.nih.gov/pubmed/32584367
http://dx.doi.org/10.1001/jamaoncol.2020.1796

Ejemplares similares